K
Kathryn Tucker
Publications - 10
Citations - 1600
Kathryn Tucker is an academic researcher. The author has contributed to research in topics: Malaria vaccine & Malaria. The author has an hindex of 10, co-authored 10 publications receiving 1488 citations.
Papers
More filters
Journal ArticleDOI
Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity
J. E. Epstein,Krishnansu S. Tewari,Kirsten E. Lyke,B. K. L. Sim,Peter F. Billingsley,Matthew B. Laurens,Matthew B. Laurens,Anusha Gunasekera,Sumana Chakravarty,Eric R. James,Martha Sedegah,Adam Richman,Soundarapandian Velmurugan,Sharina Reyes,Ming Lin Li,Kathryn Tucker,Adriana Ahumada,Adam Ruben,Tao Li,Richard E. Stafford,Abraham G. Eappen,Cindy Tamminga,Jason W. Bennett,Christian F. Ockenhouse,Jittawadee Murphy,Jack Komisar,N. Thomas,Mark Loyevsky,Ashley J. Birkett,Christopher V. Plowe,Christopher V. Plowe,Christian Loucq,Robert R. Edelman,Thomas L. Richie,Robert A. Seder,Stephen L. Hoffman +35 more
TL;DR: The results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Plasmodium falciparum malaria and suboptimally immunogenic and protective.
Journal ArticleDOI
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
Bernhards Ogutu,Odika J. Apollo,Denise McKinney,Willis Okoth,Joram Siangla,Filip Dubovsky,Kathryn Tucker,John N. Waitumbi,Carter L. Diggs,Janet Wittes,Elissa Malkin,Amanda J. Leach,Lorraine Soisson,Jessica Milman,Lucas Otieno,Carolyn A. Holland,Mark E. Polhemus,Shon Remich,Christian F. Ockenhouse,Joe Cohen,W. Ripley Ballou,Samuel K. Martin,Evelina Angov,V. Ann Stewart,Jeffrey A. Lyon,D. Gray Heppner,Mark R. Withers +26 more
TL;DR: FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator, and is not a promising candidate for further development as a monovalent malaria vaccine.
Journal ArticleDOI
Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
Michele D. Spring,James F. Cummings,Christian F. Ockenhouse,Sheetij Dutta,Randall Reidler,Evelina Angov,Elke S. Bergmann-Leitner,V. Ann Stewart,Stacey Bittner,Laure Y. Juompan,Mark G. Kortepeter,Robin Nielsen,Urszula Krzych,Ev Tierney,Lisa A. Ware,Megan Dowler,Cornelus C. Hermsen,Robert W. Sauerwein,Sake J. de Vlas,Opokua Ofori-Anyinam,David E. Lanar,Jack Williams,Kent E. Kester,Kathryn Tucker,Meng Shi,Elissa Malkin,Carole A. Long,Carter L. Diggs,Lorraine Soisson,Marie-Claude Dubois,W. Ripley Ballou,Joe Cohen,D. Gray Heppner +32 more
TL;DR: All three vaccine formulations were found to be safe and highly immunogenic and immune responses did not translate into significant vaccine efficacy in malaria-naïve adults employing a primary sporozoite challenge model, but encouragingly, estimation of parasite growth rates from qPCR data may suggest a partial biological effect of the vaccine.
Journal ArticleDOI
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
D. Gray Heppner,Kent E. Kester,Christian F. Ockenhouse,Nadia Tornieporth,Opokua Ofori,Jeffrey A. Lyon,V. Ann Stewart,Patrice M. Dubois,David E. Lanar,Urszula Krzych,Philippe Moris,Evelina Angov,James F. Cummings,Amanda J. Leach,B. Ted Hall,Sheetij Dutta,Robert Schwenk,Collette J. Hillier,Arnoldo Barbosa,Lisa A. Ware,Lalitha Nair,Christian A. Darko,Mark R. Withers,Bernhards Ogutu,Mark E. Polhemus,Mark M. Fukuda,Sathit Pichyangkul,Montip Gettyacamin,Carter L. Diggs,Lorraine Soisson,Jessica Milman,Marie-Claude Dubois,Nathalie Garçon,Kathryn Tucker,Janet Wittes,Christopher V. Plowe,Mahamadou A. Thera,Ogobara K. Duombo,Maria G. Pau,Jaap Goudsmit,W. Ripley Ballou,Joe Cohen +41 more
TL;DR: The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research is to develop a licensed multi-antigen, multi-stage vaccine able to prevent all symptomatic manifestations of malaria by preventing parasitemia.
Journal ArticleDOI
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
José A. Stoute,Joash Gombe,Mark R. Withers,Joram Siangla,Denise McKinney,Melanie Onyango,James F. Cummings,Jessica Milman,Kathryn Tucker,Lorraine Soisson,V. Ann Stewart,Jeffrey A. Lyon,Evelina Angov,Amanda J. Leach,Joe Cohen,Kent E. Kester,Christian F. Ockenhouse,Carolyn A. Holland,Carter L. Diggs,Janet Wittes,D. Gray Heppner +20 more
TL;DR: The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria.